CDK2 and lung adenocarcinoma: Based on the activity of these CDK inhibitors (Fig. S9A–C), we speculated that CDK2, CDK4/6, and CDK5 are candidates that activate DRP1 during the cell cycle in lung adenocarcinoma cell lines (Fig. 5G).